Glioblastoma: WHO Grade 4 Astrocytoma IDH-Wildtype Molecular Diagnosis MGMT Methylation Maximal Safe Resection Stupp Protocol Concurrent Temozolomide Radiotherapy Adjuvant TTFields Tumor Treating Fields Recurrence Bevacizumab Surveillance

OncologyNeuro-OncologyUpdated 2026

Glioblastoma: 2021 WHO Molecular Diagnosis, Stupp Protocol, and the Modern Treatment Landscape

The most common and most aggressive primary malignant brain tumor in adults, redefined by the 2021 WHO CNS5 classification as IDH-wildtype astrocytoma WHO grade 4. Comprehensive synthesis of molecular diagnosis (MGMT promoter methylation, EGFR amplification, TERT promoter mutation, +7/-10), maximal safe resection with intraoperative adjuncts, the Stupp protocol of concurrent temozolomide and radiotherapy followed by adjuvant temozolomide, tumor treating fields, and management of recurrence.

Executive summary. The 2021 WHO Classification of Tumors of the Central Nervous System (CNS5) restricts the term "glioblastoma" to IDH-wildtype diffuse astrocytomas with characteristic molecular features — required findings include microvascular proliferation, necrosis, OR any of three molecular markers (TERT promoter mutation, EGFR amplification, +7/-10 chromosomal copy-number changes) — even in the absence of classical histology. IDH-mutant gliomas previously called secondary glioblastoma are now reclassified as astrocytoma IDH-mutant grade 4. Diagnosis combines contrast-enhanced MRI (heterogeneous ring-enhancing mass with surrounding edema, often crossing the corpus callosum as a "butterfly glioma"), maximal safe resection guided by 5-aminolevulinic acid (5-ALA) fluorescence and intraoperative MRI/navigation, and integrated molecular pathology including MGMT promoter methylation status. The Stupp protocol — concurrent radiotherapy (60 Gy in 30 fractions) plus daily temozolomide 75 mg/m²/day PO, followed by 6 cycles of adjuvant temozolomide 150–200 mg/m²/day PO × 5 days every 28 days — remains the standard of care. MGMT-methylated tumors derive greater benefit. Tumor treating fields (TTFields) added to maintenance temozolomide improved survival in the EF-14 trial. Bevacizumab is approved for recurrence in some regions. Despite multidisciplinary care, median overall survival remains approximately 14–16 months overall (up to 21–23 months in young patients with methylated MGMT and gross-total resection), with 5-year survival of 5–10 percent.

~3–5/100k
Annual incidence
~40%
MGMT promoter methylation
14–16 mo
Median OS with standard therapy
5–10%
5-year overall survival

S1 — Molecular Pathology and 2021 WHO Classification

Glioblastoma 2021 WHO CNS5 classification, molecular drivers, and MGMT prognostic impact Three-panel figure showing the 2021 WHO CNS5 classification flow with IDH status as primary discriminator, key molecular markers (MGMT methylation, EGFR amplification, TERT promoter, +7/-10), and Kaplan-Meier-style prognostic stratification by MGMT methylation status and age. IDH Status → 2021 WHO Diagnosis → Molecular Markers → Prognostic Stratification 2021 WHO CNS5 Flow Diffuse glioma IDH1/IDH2 testing IDH-wildtype + any of: - TERT mut - EGFR amp - +7/-10 = Glioblastoma G4 IDH-mutant Astrocytoma IDH-mutant Grade 2/3/4 CDKN2A/B HD = Grade 4 (not GBM) Critical change in WHO CNS5: Molecular criteria can establish GBM diagnosis WITHOUT classical microvascular proliferation/necrosis "molecularly defined glioblastoma" Key Molecular Markers MGMT promoter methylation ~40% of GBM Silences MGMT DNA repair → better TMZ response + prognosis EGFR amplification ~40% of GBM EGFRvIII variant common TERT promoter mutation ~80% of GBM Telomerase reactivation +7/-10 (chr 7 gain / 10 loss) ~50% of GBM CDKN2A/B HD common MGMT is the practice-changing marker Survival by MGMT + Age Months from diagnosis % OS MGMT-methyl young Median ~22 mo MGMT-methyl elderly Median ~14 mo MGMT-unmeth Median ~12 mo 12 24 36 5-y OS: ~5–10% overall ~25% in MGMT-methyl young
Figure 1. 2021 WHO CNS5 classification places IDH status as the primary discriminator; IDH-wildtype astrocytomas with TERT promoter mutation, EGFR amplification, or +7/-10 are now classified as glioblastoma even without classical microvascular proliferation/necrosis. MGMT methylation is the dominant practice-changing biomarker.

Molecular pathology

The 2021 WHO Classification of Tumors of the Central Nervous System (CNS5) substantially restructured glioma diagnosis. IDH (isocitrate dehydrogenase) mutation status is the primary discriminator. IDH-wildtype diffuse astrocytomas with classical glioblastoma morphology (microvascular proliferation and/or necrosis) OR with any of three molecular features — TERT promoter mutation, EGFR amplification, or combined chromosome 7 gain and chromosome 10 loss (+7/-10) — are classified as glioblastoma IDH-wildtype WHO grade 4. This is a substantive shift: tumors that previously were called "diffuse astrocytoma" or "anaplastic astrocytoma" by histology but bear glioblastoma molecular signature now receive the glioblastoma label and management. IDH-mutant gliomas — including those previously called "secondary glioblastoma" — are now classified as astrocytoma IDH-mutant grade 2, 3, or 4 (with grade 4 defined by CDKN2A/B homozygous deletion or specific other features), and are managed differently.

Key molecular markers and their clinical use

MGMT (O-6-methylguanine-DNA methyltransferase) promoter methylation silences the DNA repair enzyme that reverses temozolomide-induced damage. Methylated tumors thus retain alkylator-induced cytotoxicity longer and respond better to temozolomide. Methylation status is determined by methylation-specific PCR or pyrosequencing on tumor tissue. Approximately 40 percent of glioblastomas are MGMT-methylated. The marker is both prognostic (better outcome regardless of treatment) and predictive (greater benefit from temozolomide). EGFR amplification (~40 percent), EGFRvIII variant (~25 percent of amplified cases), TERT promoter mutation (~80 percent), and CDKN2A/B homozygous deletion are all enriched in glioblastoma and contribute to molecular diagnosis under WHO CNS5 criteria. Comprehensive genomic profiling identifies actionable mutations in a minority (e.g., BRAF V600E in rare cases, NTRK fusions, FGFR alterations) and is increasingly performed.

Epidemiology

Glioblastoma is the most common primary malignant brain tumor in adults, with annual incidence approximately 3–5 per 100,000. Peak incidence is in the sixth and seventh decades; median age at diagnosis is approximately 65 years. Male-to-female ratio is approximately 1.6:1. Established risk factors are limited: prior therapeutic cranial irradiation, rare hereditary syndromes (Li-Fraumeni, neurofibromatosis type 1, Lynch syndrome, Turcot syndrome, Cowden syndrome). Cell phone use, head trauma, dietary factors, and electromagnetic field exposure have not been established as significant risk factors despite ongoing research.

S2 — Clinical Presentation, MRI Features, and Workup

Butterfly glioblastoma anatomy and concentric MRI signal zonesAxial brain schematic showing a bilateral frontal ring-enhancing mass crossing the corpus callosum (butterfly glioma) with three concentric zones: central necrosis facilitating diffusion, a thick irregular ring-enhancing rim with high rCBV, and surrounding FLAIR hyperintensity representing vasogenic edema plus non-enhancing tumor infiltration. Midline shift and effaced ventricle are labeled.Butterfly Glioblastoma & Concentric MRI Signal Zones (axial view)Bilateral frontal mass crossing the corpus callosum — classic but not pathognomonicA (anterior)FLAIR / T2 zone:vasogenic edema +non-enhancing tumorinfiltrationT1+C rim:thick irregularenhancing wall,high rCBVcentralnecrosisNecrotic core:DWI facilitatesdiffusion (dark)Corpus callosumtumor crosses midlineMass effect → midline shift & effaced ventricleshiftNecrosisEnhancing rimFLAIR edema / infiltration

Clinical presentation

Symptoms typically develop over weeks to a few months and depend on tumor location and surrounding edema. Common presentations include progressive headache (often worse in the morning, may be associated with nausea/vomiting from raised intracranial pressure), new-onset seizure (focal or generalized — particularly in patients without prior epilepsy after age 40), focal neurological deficit (weakness, aphasia, visual field defect, sensory changes — depending on tumor location), and cognitive/personality change. Mass effect with midline shift may cause altered consciousness. Sudden neurological deterioration may reflect intratumoral hemorrhage or seizure.

Magnetic resonance imaging

MRI sequenceTypical glioblastoma finding
T1 contrast-enhancedHeterogeneous ring-like enhancement around central necrosis; thick irregular wall
T2 / FLAIRExtensive surrounding hyperintensity (vasogenic edema + non-enhancing tumor infiltration)
Diffusion-weighted imaging (DWI)Restricted diffusion in solid components; central necrosis facilitates diffusion
Perfusion (rCBV)Elevated relative cerebral blood volume in solid tumor — distinguishes from abscess or demyelination
MR spectroscopyElevated choline, decreased NAA, sometimes elevated lipid/lactate in necrotic regions
"Butterfly" patternBilateral involvement of both frontal lobes crossing the corpus callosum — classic but not pathognomonic (lymphoma can mimic)

Multiple lesions occur in approximately 10 percent of cases (multifocal/multicentric glioblastoma). Disease typically remains supratentorial; cerebellar and brainstem involvement is uncommon. Leptomeningeal spread is rare but recognized. Advanced sequences — perfusion, spectroscopy, amino acid PET (18F-FET) — help distinguish glioblastoma from CNS lymphoma, demyelination, abscess, and metastasis when the routine MRI is equivocal.

Differential diagnosis on MRI

  • CNS lymphoma — typically restricts diffusion solidly, often periventricular, low rCBV, can shrink dramatically with steroids before biopsy (avoid steroids if lymphoma suspected and biopsy planned)
  • Cerebral metastasis — often multiple, smoother margins, less infiltrative edema relative to enhancing volume; primary cancer history; whole-body imaging
  • Cerebral abscess — DWI dramatically restricts within cavity; fever, recent infection, immunocompromise
  • Tumefactive demyelination — open-ring enhancement, less mass effect than expected, MS history
  • Other gliomas — diffuse astrocytoma (lower grade, often non-enhancing), oligodendroglioma (typically less necrosis, IDH-mutant + 1p/19q co-deleted)

Workup pre-resection

Once MRI raises high suspicion for glioblastoma, workup proceeds toward histologic and molecular diagnosis through biopsy or resection. Key elements include: corticosteroids (dexamethasone) for symptomatic edema or mass effect (lowest effective dose; consider holding if CNS lymphoma is possible and biopsy is imminent), antiepileptic prophylaxis or treatment for any seizure activity (levetiracetam is preferred — no hepatic interactions with chemotherapy; phenytoin and carbamazepine avoided due to enzyme induction), DVT prophylaxis in immobilized patients, MRI of the spine in selected cases (rare leptomeningeal spread), CT chest/abdomen/pelvis or whole-body imaging if metastatic disease is in differential (uncommon for primary glioma but standard for new brain mass workup), and multidisciplinary tumor board discussion at a comprehensive cancer center.

S3 — Surgery: Maximal Safe Resection

Surgical resection is the foundation of glioblastoma management. The goal is maximal safe resection — gross-total resection (≥ 95–98 percent of enhancing tumor) when feasible without unacceptable functional cost. Extent of resection correlates with survival in multiple retrospective and prospective analyses, particularly in MGMT-methylated tumors.

Surgical adjuncts

AdjunctPurposeEvidence
5-aminolevulinic acid (5-ALA) fluorescence-guided resectionOral 5-ALA preoperatively → tumor cells fluoresce pink under blue light at 405 nm; identifies infiltrating margins invisible to white lightIncreases gross-total resection rate from ~36% to ~65% (Stummer et al. RCT)
Intraoperative MRIReal-time imaging after preliminary resection to identify residual enhancing tumorIncreases extent of resection in eloquent-area tumors
Awake craniotomy with language/motor mappingDirect cortical stimulation to identify and preserve eloquent areas (Broca, Wernicke, motor cortex)Reduces postoperative neurologic deficit in eloquent-area tumors
Intraoperative neurophysiologic monitoringMotor evoked potentials, somatosensory evoked potentials, subcortical motor mappingStandard adjunct for tumors adjacent to motor pathways
Neuronavigation (frameless stereotaxy)Image-guided tracking of instruments relative to preoperative MRIStandard of care; affected by brain shift during resection
Carmustine wafers (Gliadel)Implantable BCNU wafers in resection cavityModest survival benefit in selected cases; widely supplanted by Stupp protocol

Resection categories

  • Gross-total resection (GTR) — ≥ 95–98 percent of enhancing tumor removed on postoperative MRI within 72 hours; associated with the longest survival
  • Subtotal resection — partial debulking; improves intracranial pressure and reduces tumor burden but does not achieve survival benefit comparable to GTR
  • Biopsy only — appropriate when tumor is in eloquent or deep locations precluding resection, in poor performance status, or when histologic confirmation is needed before non-surgical therapy

Recovery and adjuncts

Postoperative MRI within 24–72 hours documents extent of resection before postoperative changes obscure interpretation. Pathology and molecular workup proceed in parallel. Steroids are typically tapered postoperatively as tolerated. Wound healing is preserved; bevacizumab is avoided in the perioperative period (typically > 28 days before/after surgery) because of impaired wound healing. Antiepileptic management continues; levetiracetam 500–1500 mg PO BID is the standard. Rehabilitation begins early when neurologic deficits are present.

S4 — Stupp Protocol: Chemoradiation and Adjuvant Temozolomide

The Stupp protocol — concurrent radiotherapy plus daily temozolomide followed by adjuvant temozolomide — has been the standard of care since the 2005 EORTC-NCIC trial demonstrated survival benefit. Modifications for elderly patients and patients with poor performance status apply.

Concurrent chemoradiation phase

ComponentStandard regimenNotes
Radiotherapy60 Gy in 30 fractions of 2 Gy over 6 weeksTargets MRI enhancing volume + 2–3 cm margin (clinical target volume)
Concurrent temozolomide75 mg/m²/day PO daily during radiotherapy (7 days/week)On empty stomach (preferably bedtime); duration matches RT
Pneumocystis jirovecii prophylaxisTMP-SMX or alternatives during chemoradiation + 4 weeks afterLymphopenia risk; PJP prophylaxis is standard
Antiemetics5-HT3 antagonists (ondansetron) for daily TMZTake 30–60 min before TMZ dose

Adjuvant temozolomide

Following completion of chemoradiation and a 4-week treatment break, six cycles of adjuvant temozolomide are administered: 150 mg/m²/day PO × 5 days every 28 days for cycle 1, then escalated to 200 mg/m²/day × 5 days every 28 days for cycles 2–6 if tolerated. Extension beyond 6 cycles ("metronomic" or extended TMZ) has been studied with mixed results and is institution-dependent. Toxicities include cumulative myelosuppression (thrombocytopenia is dose-limiting in many patients), nausea, lymphopenia, fatigue, and rare hematologic malignancies with prolonged use.

Elderly and poor performance status modifications

  • Age ≥ 65–70 with good performance status — standard Stupp protocol is appropriate
  • Age > 65–70 with frailty or significant comorbidity — hypofractionated radiotherapy (40.05 Gy in 15 fractions over 3 weeks) plus concurrent and adjuvant TMZ produces comparable survival with less toxicity (Perry et al., Lancet Oncol 2017)
  • MGMT-methylated elderly patient unable to tolerate combined therapy — TMZ monotherapy is an option; reasonable response in methylated tumors
  • MGMT-unmethylated elderly patient unable to tolerate combined therapy — short-course RT alone is an option; TMZ adds little benefit without methylation
  • Very poor performance status (KPS < 60) — best supportive care; selective short-course RT for palliation
Glioblastoma treatment timeline Timeline algorithm from diagnosis through surgery, Stupp chemoradiation, adjuvant temozolomide, optional TTFields, surveillance, and recurrence management. Treatment timeline — Stupp protocol with modern enhancements Week 1: Diagnosis & surgery MRI + biopsy/resection 5-ALA + intraop MRI Molecular workup Weeks 5–10: Concurrent chemoradiation RT 60 Gy / 30 fx + Daily TMZ 75 mg/m² PJP prophylaxis Months 4–10: Adjuvant phase + maintenance TMZ 150–200 mg/m² × 6 cycles ± TTFields (EF-14) MRI surveillance q2–3 mo Recurrence: re-op / bev / clinical trial
Figure 2. Treatment timeline integrates surgery with molecular characterization, the Stupp protocol concurrent chemoradiation, adjuvant TMZ with optional TTFields, and surveillance with timely recurrence management.

S5 — Tumor Treating Fields, Recurrence, and Surveillance

Tumor treating fields (TTFields)

Median overall survival by glioblastoma treatment strategyHorizontal bar chart comparing median overall survival in months: radiotherapy alone historical baseline approximately 12 months, MGMT-unmethylated approximately 12 months, elderly hypofractionated regimen approximately 14 months, Stupp protocol overall 14 to 16 months, Stupp plus tumor treating fields 20.9 months from the EF-14 trial versus 16.0 months control, and best MGMT-methylated young subgroup up to 22 to 23 months. A separate annotation shows the EF-14 survival gain of roughly 4.9 months.Median Overall Survival by Treatment StrategyMonths from diagnosis — approximate values from cited trials and series510152025Median overall survival (months)RT alone (historical)~12 moMGMT-unmethylated~12 moElderly hypofractionated + TMZ~14 moStupp protocol (overall)14–16 moEF-14 control (TMZ only)16.0 moStupp + TTFields (EF-14)20.9 moMGMT-methylated, young, GTR22–23 moEF-14 gain ≈ +4.9 moBenefit of TTFields correlates with adherence ≥ 18 hours/day; 5-year overall survival remains ~5–10% overall.

TTFields (Optune) deliver low-intensity (1–3 V/cm) intermediate-frequency (200 kHz) alternating electric fields via skin-applied transducer arrays. The mechanism is disruption of mitotic spindle assembly. The EF-14 trial randomized patients to standard adjuvant TMZ ± TTFields and demonstrated median OS improvement from 16.0 to 20.9 months. TTFields is FDA-approved and offered to patients with newly diagnosed glioblastoma after completion of chemoradiation, typically maintained for 18+ months or until progression. Adherence (≥ 18 hours/day) correlates with benefit. Limitations include cost, scalp irritation, the requirement for shaved scalp, social and lifestyle adjustments, and uneven global availability and insurance coverage. Adoption varies substantially by region.

Surveillance MRI

MRI surveillance is performed at 4 weeks post-radiotherapy completion (to assess for pseudoprogression), then every 2–3 months during adjuvant therapy and surveillance, transitioning to every 3–4 months in stable patients after 1–2 years. The Response Assessment in Neuro-Oncology (RANO) criteria standardize response assessment using changes in T1 contrast-enhancing volume, T2/FLAIR, clinical status, and steroid use.

Pseudoprogression versus true progression

Pseudoprogression versus true progression decision treeA branching decision tree for new MRI worsening after chemoradiation. It asks whether worsening is within 3 months of chemoradiation completion, whether MGMT is methylated, whether new enhancement is inside or outside the radiation field, and whether advanced imaging shows high rCBV and restricted diffusion, leading to pseudoprogression (continue therapy, repeat MRI in 4 to 8 weeks) versus true progression (treat as recurrence) branches.Pseudoprogression vs True Progression — First Post-CRT MRINew MRI worsening afterchemoradiation completionWithin 3 monthsof CRT end?NOFavor TRUE progressionlater onset less typicalYESMGMT methylated?(enriches pseudoprog.)Enhancement OUTSIDEradiation field?YESFavor TRUE progressionnew enhancement out of fieldNO (in-field)High rCBV +restricted diffusion?YESAdvanced features favorprogression — MDT reviewNOPSEUDOPROGRESSION likelyContinue standard adjuvant therapyRepeat MRI in 4–8 weeks; do not switchAffects ~20–30% of patientsIf uncertain at any node:perfusion MRI, MR spectroscopy,amino-acid PET (18F-FET),and multidisciplinary review

Pseudoprogression — transient MRI worsening within the first 3 months after chemoradiation completion — affects approximately 20–30 percent of patients and is more common in MGMT-methylated tumors (where it actually correlates with better outcome). It reflects treatment-induced inflammatory response and resolves spontaneously on subsequent imaging without therapy change. Continuing standard adjuvant therapy and repeating MRI in 4–8 weeks is appropriate. True progression is distinguished by progressive worsening on serial imaging, clinical deterioration, increasing enhancement outside the radiation field, or advanced imaging features (high rCBV on perfusion, restricted diffusion). When uncertain, multidisciplinary review and advanced imaging (perfusion MRI, MR spectroscopy, amino acid PET — 18F-FET or 11C-methionine) often clarify.

Recurrence management

Median time to recurrence is approximately 7 months. Modal recurrence is local within 2 cm of the original tumor (~80 percent); distant recurrence is less common. Options at recurrence are individualized by performance status, location, prior therapy, time since prior therapy, and patient preference:

  • Re-resection — for selected patients with focal accessible recurrence, good performance status, and significant interval since initial surgery; some benefit suggested
  • Re-irradiation — selectively offered with stereotactic techniques for small focal recurrences distant from prior high-dose volume
  • Bevacizumab — anti-VEGF monoclonal antibody, FDA-approved for recurrent glioblastoma in the US (not approved in all regions). Improves progression-free survival, reduces steroid requirement, but does not consistently improve overall survival. Steroid-sparing effect is the most reliable clinical benefit. Dose 10 mg/kg IV every 2 weeks or 15 mg/kg every 3 weeks. Adverse effects include hypertension, proteinuria, thromboembolism, bleeding, GI perforation, impaired wound healing
  • Lomustine (CCNU) — alkylating agent; cumulative thrombocytopenia is dose-limiting; 110 mg/m² PO every 6 weeks
  • Clinical trial enrollment — strongly preferred when available; immunotherapy combinations, targeted therapies, oncolytic viruses, CAR-T therapies all under active investigation
  • TTFields continuation or initiation — selectively for recurrence
  • Best supportive care — appropriate for very poor performance status; symptom-focused with steroids, antiepileptics, palliative care integration

Symptom management

SymptomManagement
Cerebral edemaDexamethasone 4–16 mg/day PO divided at lowest effective dose; avoid prolonged high dose (Cushingoid, myopathy, hyperglycemia, immunosuppression)
SeizuresLevetiracetam first-line (no hepatic interactions); lacosamide, valproate alternatives; avoid enzyme-inducing AEDs (phenytoin, carbamazepine, phenobarbital) which interact with TMZ and bevacizumab
HeadacheSteroid optimization; acetaminophen; opioids if needed; address ICP increase if rising
Venous thromboembolismHigher incidence in glioblastoma (~20% over disease course); LMWH or DOAC for treatment (DOACs increasingly used); prophylactic anticoagulation perioperative
Fatigue / cognitive symptomsModafinil and methylphenidate have been studied; sleep hygiene; rehabilitation
End-of-life carePalliative care integration early; advance care planning; hospice referral when appropriate
When to refer. Refer to a comprehensive neuro-oncology center with multidisciplinary tumor board for all suspected glioblastoma — neurosurgical experience with intraoperative adjuncts (5-ALA, intraoperative MRI, awake mapping), modern radiation oncology, neuro-oncology medical expertise, neuropathology with molecular profiling, palliative care integration, and clinical trial access are essential. Outcomes correlate with center volume and multidisciplinary coordination. Refer at recurrence for clinical trial consideration.

S6 — Practice Insights — Synthesized Patterns for Glioblastoma Care

(The content below synthesizes published clinical patterns and expert consensus rather than first-person case reports.) Across published practice patterns, experienced clinicians have learned that glioblastoma care succeeds when molecular characterization (IDH and MGMT) is complete before treatment decisions, when maximal safe resection is pursued at high-volume centers with intraoperative adjuncts, and when early post-chemoradiation MRI is interpreted with pseudoprogression in mind rather than as automatic treatment failure.

What the Guideline Under-Emphasizes

Guidelines list molecular workup as routine, but experienced practice has learned that delays in molecular results frequently extend the time from diagnosis to systemic therapy. Establishing a rapid-turnaround molecular pathway at the institution — ideally with IDH and MGMT results available within 1–2 weeks of surgery — meaningfully shortens the gap to Stupp protocol initiation and aligns therapy with biology from cycle 1.

Patterns Experienced Clinicians Track

Across published cohorts, the first surveillance MRI 4 weeks after chemoradiation completion shows worsening in 20–30 percent of patients — and this pattern is enriched in MGMT-methylated tumors where it correlates with better outcome. Experienced practice does not switch therapy on the first apparent progression scan in this window; serial imaging at 4–8 weeks usually clarifies pseudoprogression from true progression.

The Bedside Heuristic

A practical management framework at each milestone answers three questions: Has molecular characterization been completed and integrated into the treatment plan? Has the patient been offered enrollment in any open clinical trial appropriate for their stage and tumor profile? Have advance care planning and palliative care services been introduced — not at end-stage, but proactively at diagnosis? Affirmatives to all three reflect modern comprehensive care; gaps drive the most preventable harms.

Illustrative Scenario — Mr. G

An illustrative scenario describes a man in his late fifties (composite from literature patterns) presenting with three weeks of progressive right-sided weakness and a new-onset focal seizure. MRI demonstrated a 4 cm heterogeneously ring-enhancing left frontal mass with extensive surrounding FLAIR hyperintensity crossing the corpus callosum. Awake craniotomy with motor and language mapping and intraoperative 5-ALA achieved gross-total resection of the enhancing tumor. Pathology confirmed IDH-wildtype glioblastoma WHO grade 4 with TERT promoter mutation and EGFR amplification; MGMT promoter was methylated. Postoperative neurologic status returned to near-baseline. The Stupp protocol was initiated 4 weeks post-resection with 60 Gy in 30 fractions plus daily TMZ 75 mg/m². TTFields was offered and accepted, initiated 1 month after chemoradiation completion alongside adjuvant TMZ. The 4-week post-RT MRI showed apparent progression at the resection margin; advanced imaging supported pseudoprogression, and repeat MRI 6 weeks later demonstrated resolution. Adjuvant TMZ completed 6 cycles. At 22 months from diagnosis, the patient was on TTFields maintenance with stable disease.

What this scenario teaches: Maximal safe resection with intraoperative adjuncts (5-ALA, awake mapping) at a high-volume center enables aggressive resection even in eloquent areas. Molecular markers (MGMT methylation, IDH-wildtype status, TERT, EGFR amplification) frame both diagnostic classification and prognostic discussion. Pseudoprogression in MGMT-methylated tumors should not trigger premature therapy switch — serial imaging within 4–8 weeks usually clarifies.

Practice Pattern Refinements

  1. Confirm IDH status and MGMT methylation before treatment decisions. The 2021 WHO CNS5 classification places IDH at the diagnostic root; MGMT methylation guides the magnitude of expected benefit from temozolomide. Modern molecular turnaround is 1–2 weeks at high-volume centers; insisting on this timeline at the institutional level shortens delay to therapy.
  2. Pursue maximal safe resection at a high-volume center with intraoperative adjuncts. 5-ALA fluorescence increases gross-total resection rate from approximately 36 to 65 percent; intraoperative MRI and awake mapping further improve resection in eloquent locations. Extent of resection correlates strongly with survival; community-volume surgery without adjuncts may achieve substantially less.
  3. Use levetiracetam — not phenytoin or carbamazepine — for seizure management. Enzyme-inducing antiepileptics interact with temozolomide and bevacizumab metabolism. Levetiracetam has no significant chemotherapy interactions and is the modern standard for glioblastoma-associated seizures.
  4. Treat the first surveillance MRI with pseudoprogression in mind. Apparent worsening on the 4-week post-RT MRI affects 20–30 percent of patients and is enriched in MGMT-methylated tumors (where it correlates with better outcome). Continuing standard therapy with repeat MRI in 4–8 weeks usually clarifies; premature switch to recurrence therapy in pseudoprogression abandons effective ongoing treatment.

S7 — Frequently Asked Questions

Q1. What is the prognosis of glioblastoma?

Median overall survival with standard therapy is approximately 14–16 months overall, with 5-year survival of 5–10 percent. Best outcomes (median OS up to 21–23 months and 5-year survival approaching 20–25 percent) occur in younger patients (< 50 years) with good performance status, MGMT promoter methylation, and gross-total resection. Worst outcomes occur in elderly patients with poor performance status and MGMT-unmethylated tumors. Despite multidisciplinary care advances, glioblastoma remains one of the most aggressive human cancers.

Q2. What does MGMT methylation mean for treatment?

MGMT (O-6-methylguanine-DNA methyltransferase) promoter methylation silences a DNA repair enzyme that reverses temozolomide-induced DNA damage. Methylated tumors retain alkylator-induced cytotoxicity longer and respond better to temozolomide. The marker is both prognostic (better outcome regardless of treatment) and predictive (greater benefit from TMZ). Approximately 40 percent of glioblastomas are MGMT-methylated. In elderly patients unable to tolerate combined chemoradiation, MGMT methylation status helps decide between TMZ monotherapy (methylated) and short-course RT alone (unmethylated, where TMZ adds little benefit).

Q3. Are tumor treating fields worth pursuing?

The EF-14 trial demonstrated that TTFields added to standard adjuvant TMZ improved median overall survival from 16.0 to 20.9 months in newly diagnosed glioblastoma. Benefit correlates with adherence (≥ 18 hours per day). Limitations include cost, scalp irritation, the requirement for shaved scalp, social and lifestyle adjustments, and uneven global availability and insurance coverage. The decision balances projected survival benefit against quality-of-life impact and is individualized; patients should be offered the option with clear discussion of practicalities.

Q4. What is pseudoprogression?

Pseudoprogression is transient MRI worsening within the first 3 months after chemoradiation completion, affecting approximately 20–30 percent of patients and more common in MGMT-methylated tumors. It reflects treatment-induced inflammatory response, not true tumor progression, and resolves spontaneously on serial imaging. Continuing standard adjuvant therapy and repeating MRI in 4–8 weeks is appropriate. True progression is distinguished by progressive worsening on serial imaging, clinical deterioration, enhancement outside the radiation field, or supporting advanced imaging features (high rCBV, restricted diffusion).

Q5. What are the options at recurrence?

Options at recurrence are individualized by performance status, recurrence location, prior therapy, time since prior therapy, and patient preference. Re-resection is considered for focal accessible recurrence with good performance status. Re-irradiation with stereotactic techniques is selectively offered for small focal recurrences. Bevacizumab improves progression-free survival, reduces steroid requirement, but does not consistently improve overall survival — its steroid-sparing effect is the most reliable benefit. Lomustine is an alkylating option. Clinical trial enrollment is strongly preferred when available. Best supportive care with palliative integration is appropriate for very poor performance status.

Q6. Should the family undergo genetic testing?

Most glioblastoma is sporadic. Hereditary cancer syndromes account for less than 5 percent of cases — Li-Fraumeni (TP53), neurofibromatosis type 1, Lynch syndrome, Turcot syndrome, Cowden syndrome are the recognized predispositions. Genetic counseling and germline testing are appropriate when family history is suggestive (early-onset cancers, multiple primary cancers, multiple affected relatives) or when tumor sequencing identifies a pathogenic germline-suspicious variant. Routine genetic testing of all patients is not currently recommended outside these contexts.

Leave a Reply

Your email address will not be published. Required fields are marked *